Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis
Abstract
Background & aims Proof-of-concept studies frequently assess changes in intrahepatic triglyceride (IHTG) content by magnetic resonance-based techniques as a surrogate marker of histology. The aim of this study was to establish how reliable this strategy is to predict changes in liver histology in patients with non-alcoholic steatohepatitis (NASH).Methods Patients with NASH who had participated in our prior randomized controlled trials of pioglitazone with complete paired data for IHTG content by magnetic resonance spectroscopy and liver histology were included in the study.Results A total of 121 patients were included. Changes in IHTG were assessed in several ways: as a continuous variable (correlations), as categorical groups (IHTG change ≥0%; or IHTG reduction of 1-30%; 31-50%; 51-70%; or >70%), and in a binomial way as steatosis resolution or not (defined as achieving IHTG <5.56%). Changes in IHTG correlated with steatosis on histology (r = 0.54; p <0.01). However, the magnitude of IHTG reduction was not associated with the rate of response of the primary histological outcome (2-point improvement in the NAFLD activity score from 2 different parameters, without worsening of fibrosis) or resolution of NASH without worsening of fibrosis, neither in patients receiving pioglitazone nor placebo. Changes in lobular inflammation, hepatocyte ballooning, or liver fibrosis were also independent of changes in IHTG, irrespective of treatment arm. Steatosis resolution was not associated with better histological outcomes either.Conclusions Changes in IHTG predict changes in steatosis but not of other liver histological parameters. This implies that IHTG response to treatment should be interpreted with caution, as it may not be as reliable as previously believed to predict a treatment's overall clinical efficacy in patients with NASH.Lay summary Quantification of liver fat by magnetic resonance imaging (MRI) is currently used to assess treatment responses in patients with fatty liver, with the assumption that improvements in liver fat translate into less inflammation, necrosis, and fibrosis in the liver. However, in this article, we showed that changes in liver fat do not necessarily translate into changes in these parameters. This means that MRI may not be as useful to assess treatment response in patients with fatty liver as previously believed.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The prediction of fibrosis regression by MRI-PDFF reduction was not unanimously confirmed.
“though this was not unanimously con fi rmed. 269,270”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [270]
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791 · see citing works
Standards of Medical Care in Diabetes
Power, D. V. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1593 · Cited by 8,672 · see citing works
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239 · see citing works
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327 · see citing works
Vilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., Torres-Gonzalez, A., Gra-Oramas, B., Gonzalez-Fabian, L., Friedman, S. L., Diago, M., & Romero-Gomez, M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.005 · Cited by 2,492 · see citing works
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237 · see citing works
Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203 · see citing works
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827 · see citing works
Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis
Promrat, K., Kleiner, D. E., Niemeier, H. M., Jackvony, E., Kearns, M., Wands, J. R., Fava, J. L., & Wing, R. R. (2010) · Hepatology · doi:10.1002/hep.23276 · Cited by 1,330 · see citing works
Ratziu, V., Harrison, S. A., Francque, S., Bedossa, P., Lehert, P., Serfaty, L., Romero-Gomez, M., Boursier, J., Abdelmalek, M., Caldwell, S., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.038 · Cited by 1,035 · see citing works
Cusi, K., Orsak, B., Bril, F., Lomonaco, R., Hecht, J., Ortiz-Lopez, C., Tio, F., Hardies, J., Darland, C., Musi, N., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m15-1774 · Cited by 1,024 · see citing works
Yamaguchi, K., Yang, L., McCall, S. J., Huang, J., Yu, X. X., Pandey, S., Bhanot, S., Monia, B. P., Li, Y.-X., & Diehl, A. M. (2007) · Hepatology · doi:10.1002/hep.21655 · Cited by 1,019 · see citing works
Friedman, S. L., Ratziu, V., Harrison, S. A., Abdelmalek, M. F., Aithal, G. P., Caballeria, J., Francque, S., Farrell, G., Kowdley, K. V., Craxi, A., et al. (2018) · Hepatology · doi:10.1002/hep.29477 · Cited by 671 · see citing works
Ratziu, V., Giral, P., Jacqueminet, S., Charlotte, F., Hartemann–Heurtier, A., Serfaty, L., Podevin, P., Lacorte, J., Bernhardt, C., Bruckert, E., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.078 · Cited by 625 · see citing works
Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease
Kumashiro, N., Erion, D. M., Zhang, D., Kahn, M., Beddow, S. A., Chu, X., Still, C. D., Gerhard, G. S., Han, X., Dziura, J., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1113359108 · Cited by 585 · see citing works
Noureddin, M., Lam, J., Peterson, M. R., Middleton, M., Hamilton, G., Le, T.-A., Bettencourt, R., Changchien, C., Brenner, D. A., Sirlin, C., et al. (2013) · Hepatology · doi:10.1002/hep.26455 · Cited by 550 · see citing works
Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal
Alkhouri, N., Dixon, L. J., & Feldstein, A. E. (2009) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/egh.09.32 · Cited by 400 · see citing works
Harrison, S. A., Abdelmalek, M. F., Caldwell, S., Shiffman, M. L., Diehl, A. M., Ghalib, R., Lawitz, E. J., Rockey, D. C., Schall, R. A., Jia, C., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.07.006 · Cited by 384 · see citing works
Younossi, Z. M., Loomba, R. S., Rinella, M. E., Bugianesi, E., Marchesini, G., Neuschwander‐Tetri, B. A., Serfaty, L., Negro, F., Caldwell, S. H., Ratziu, V., et al. (2017) · Hepatology · doi:10.1002/hep.29724 · Cited by 382 · see citing works
Ratziu, V., Charlotte, F., Bernhardt, C., Giral, P., Halbron, M., Naour, G. L., Hartemann–Heurtier, A., Bruckert, É., & Poynard, T. (2009) · Hepatology · doi:10.1002/hep.23270 · Cited by 363 · see citing works
Sanyal, A. J., Friedman, S. L., McCullough, A. J., & Dimick‐Santos, L. (2014) · Hepatology · doi:10.1002/hep.27678 · Cited by 355 · see citing works
Xia, J. Y., Holland, W. L., Kusminski, C. M., Sun, K., Sharma, A. X., Pearson, M. J., Sifuentes, A. J., McDonald, J. G., Gordillo, R., & Scherer, P. E. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.06.007 · Cited by 348 · see citing works
Loomba, R. S., Sirlin, C. B., Ang, B., Bettencourt, R., Jain, R., Salotti, J., Soaft, L., Hooker, J. C., Kono, Y., Bhatt, A., et al. (2014) · Hepatology · doi:10.1002/hep.27647 · Cited by 346 · see citing works
Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action
Bril, F., & Cusi, K. (2017) · Diabetes Care · doi:10.2337/dc16-1787 · Cited by 341 · see citing works
Self-citationPathological Features of Fatty Liver Disease
Yeh, M. M., & Brunt, E. M. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.07.056 · Cited by 339 · see citing works
Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial
Cui, J. Y., Philo, L., Nguyen, P., Hofflich, H., Hernandez, C., Bettencourt, R., Richards, L., Salotti, J., Bhatt, A., Hooker, J. C., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.04.021 · Cited by 327 · see citing works
Bril, F., Biernacki, D. M., Kalavalapalli, S., Lomonaco, R., Subbarayan, S. K., Lai, J., Tio, F., Suman, A., Orsak, B. K., Hecht, J., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0167 · Cited by 312 · see citing works
Role of ceramides in nonalcoholic fatty liver disease
Pagadala, M. R., Kasumov, T., McCullough, A. J., Zein, N. N., & Kirwan, J. P. (2012) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2012.04.005 · Cited by 306 · see citing works
Bril, F., Barb, D., Portillo-Sánchez, P., Biernacki, D., Lomonaco, R., Suman, A., Weber, M. H., Budd, J. T., Lupi, M. E., & Cusi, K. J. (2016) · Hepatology · doi:10.1002/hep.28985 · Cited by 291 · see citing works
Apostolopoulou, M., Gordillo, R., Koliaki, C., Gancheva, S., Jelenik, T., De Filippo, E., Herder, C., Markgraf, D., Jankowiak, F., Esposito, I., et al. (2018) · Diabetes Care · doi:10.2337/dc17-1318 · Cited by 284 · see citing works
Middleton, M. S., Heba, E. R., Hooker, C. A., Bashir, M. R., Fowler, K. J., Sandrasegaran, K., Brunt, E. M., Kleiner, D. E., Doo, E. C., Natta, M. L. V., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.06.005 · Cited by 278 · see citing works
Bril, F., Ortiz‐Lopez, C., Lomonaco, R., Orsak, B., Freckleton, M. W., Chintapalli, K. N., Hardies, J., Lai, S., Solano, F., Tio, F. O., et al. (2015) · Liver International · doi:10.1111/liv.12840 · Cited by 237 · see citing works
Petit, J., Cercueil, J., Loffroy, R., Denimal, D., Bouillet, B., Fourmont, C., Chevallier, O., Duvillard, L., & Vergès, B. L. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2775 · Cited by 228 · see citing works
Intrahepatic Diacylglycerol Content Is Associated With Hepatic Insulin Resistance in Obese Subjects
Magkos, F., Su, X., Bradley, D. P., Fabbrini, E., Conte, C., Eagon, J. C., Varela, J. E., Brunt, E. M., Patterson, B. W., & Klein, S. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.03.003 · Cited by 223 · see citing works
Jayakumar, S., Middleton, M. S., Lawitz, E. J., Mantry, P. S., Caldwell, S. H., Arnold, H., Mae Diehl, A., Ghalib, R., Elkhashab, M., Abdelmalek, M. F., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.09.024 · Cited by 208 · see citing works
Bril, F., Kalavalapalli, S., Clark, V. C., Lomonaco, R., Soldevila-Pico, C., Liu, I.-C., Orsak, B., Tio, F., & Cusi, K. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.12.001 · Cited by 199 · see citing works
The Metabolically Benign and Malignant Fatty Liver
Stefan, N., & Häring, H. (2011) · Diabetes · doi:10.2337/db11-0231 · Cited by 172 · see citing works
ter Horst, K. W., Gilijamse, P. W., Versteeg, R. I., Ackermans, M. T., Nederveen, A. J., la Fleur, S. E., Romijn, J. A., Nieuwdorp, M., Zhang, D., Samuel, V. T., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.05.035 · Cited by 166 · see citing works
Patel, J. R., Bettencourt, R., Cui, J. Y., Salotti, J., Hooker, J. C., Bhatt, A., Hernandez, C., Nguyen, P., Aryafar, H., Valasek, M. A., et al. (2016) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x16656735 · Cited by 163 · see citing works
Lipotoxicity in steatohepatitis occurs despite an increase in tricarboxylic acid cycle activity
Patterson, R. E., Kalavalapalli, S., Williams, C. M., Nautiyal, M., Mathew, J. T., Martinez, J., Reinhard, M. K., McDougall, D. J., Rocca, J. R., Yost, R. A., et al. (2016) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00492.2015 · Cited by 161 · see citing works
Kalavalapalli, S., Bril, F., Koelmel, J. P., Abdo, K. I., Guingab, J., Andrews, P. M., Li, W., Jose, D., Yost, R. A., Frye, R. F., et al. (2018) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00023.2018 · Cited by 66 · see citing works
Summary of Revisions: Standards of Medical Care in Diabetes—2019
(2018) · Diabetes Care · doi:10.2337/dc19-srev01 · Cited by 62 · see citing works
Younossi, Z. M., Ratziu, V., Loomba, R. S., Rinella, M. E., Anstee, Q. M., Goodman, Z. D., Bédossa, P., Geier, A., Beckebaum, S., Newsome, P. N., et al. (2019) · Journal of Hepatology · doi:10.1016/s0618-8278(19)30006-4 · Cited by 55 · see citing works
Impact of exenatide on mitochondrial lipid metabolism in mice with nonalcoholic steatohepatitis
Kalavalapalli, S., Bril, F., Guingab, J., Vergara, A., Garrett, T. J., Sunny, N. E., & Cusi, K. J. (2019) · Journal of Endocrinology · doi:10.1530/joe-19-0007 · Cited by 50 · see citing works
Harrison, S. A., Guy, C. D., Taub, R. A., & Bashir, M. R. (2019) · Journal of Hepatology · doi:10.1016/s0618-8278(19)31577-4 · Cited by 1 · see citing works
Flagged first, then by citations
2 of the 47 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Tacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.031 · Cited by 2,210 · see citing works
Berzigotti, A., Tsochatzis, E., Boursier, J., Castera, L., Cazzagon, N., Friedrich-Rust, M., Petta, S., & Thiele, M. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.05.025 · Cited by 1,925 · see citing works
Eslam, M., Sarin, S. K., Wong, V. W., Fan, J.-G., Kawaguchi, T., Ahn, S. H., Zheng, M., Shiha, G. E.-S., Yilmaz, Y. N., Gani, R. A., et al. (2020) · Hepatology International · doi:10.1007/s12072-020-10094-2 · Cited by 837 · see citing works
Gastaldelli, A., Cusi, K., Fernández Landó, L., Bray, R., Brouwers, B., & Rodríguez, Á. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00070-5 · Cited by 513 · see citing works
(2024) · Obesity Facts · doi:10.1159/000539371 · Cited by 510 · see citing works
Challenges and opportunities in NASH drug development
Harrison, S. A., Allen, A. M., Dubourg, J., Noureddin, M., & Alkhouri, N. (2023) · Nature Medicine · doi:10.1038/s41591-023-02242-6 · Cited by 353 · see citing works
Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD
Tamaki, N., Ajmera, V. H., & Loomba, R. S. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00584-0 · Cited by 254 · see citing works
Ratziu, V., de Guevara, L., Safadi, R., Poordad, F., Fuster, F., Flores-Figueroa, J., Arrese, M., Fracanzani, A. L., Ben Bashat, D., Lackner, K., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01495-3 · Cited by 222 · see citing works
Perakakis, N., Stefanakis, K., & Mantzoros, C. S. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154320 · Cited by 163 · see citing works
Clinical Trial Landscape in NASH
Harrison, S. A., Loomba, R. S., Dubourg, J., Ratziu, V., & Noureddin, M. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.03.041 · Cited by 140 · see citing works
Mantovani, A., Petracca, G., Csermely, A., Beatrice, G., & Targher, G. (2020) · Metabolites · doi:10.3390/metabo11010022 · Cited by 136 · see citing works
Breakthroughs in therapies for NASH and remaining challenges
Ratziu, V., Francque, S., & Sanyal, A. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.04.002 · Cited by 132 · see citing works
EDP-305 in patients with NASH: a phase II double-blind placebo-controlled dose-ranging study
Ratziu, V., Rinella, M. E., Neuschwander-Tetri, B. A., Lawitz, E., Denham, D., Kayali, Z., Sheikh, A., Kowdley, K. V., Desta, T., Elkhashab, M., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.10.018 · Cited by 123 · see citing works
Ratziu, V., Harrison, S. A., Loustaud-Ratti, V., Bureau, C., Lawitz, E., Abdelmalek, M., Alkhouri, N., Francque, S., Girma, H., Darteil, R., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2022.10.023 · Cited by 101 · see citing works
Harrison, S. A., Thang, C., Bolze, S., Dewitt, S., Hallakou-Bozec, S., Dubourg, J., Bedossa, P., Cusi, K., Ratziu, V., Grouin, J.-M., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.02.004 · Cited by 96 · see citing works
Cusi, K. J., Alkhouri, N., Harrison, S. A., Fouqueray, P., Moller, D. E., Hallakou‐Bozec, S., Bolze, S., Grouin, J., Megnien, S. J., Dubourg, J., et al. (2021) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(21)00300-9 · Cited by 78 · see citing works
Time to Include Nonalcoholic Steatohepatitis in the Management of Patients With Type 2 Diabetes
Cusi, K. J. (2020) · Diabetes Care · doi:10.2337/dci19-0064 · Cited by 69 · see citing works
Non-invasive tests of non-alcoholic fatty liver disease
Li, G., Zhang, X., Lin, H., Liang, L. Y., Wong, G. L., & Wong, V. W. (2022) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002027 · Cited by 56 · see citing works
Cusi, K. J. (2020) · Liver International · doi:10.1111/liv.14350 · Cited by 52 · see citing works
Obeticholic acid for the treatment of nonalcoholic steatohepatitis
Shah, R. A., & Kowdley, K. V. (2020) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2020.1748498 · Cited by 42 · see citing works
Lavynenko, O., Abdul‐Ghani, M., Alatrach, M., Puckett, C., Adams, J., Abdelgani, S., Alkhouri, N., Triplitt, C., Clarke, G. D., Vasquez, J. A., et al. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14650 · Cited by 44 · see citing works
Insulin resistance is an integral feature of MASLD even in the presence of PNPLA3 variants
Bril, F., Kalavalapalli, S., Lomonaco, R., Frye, R. F., Leiva, E. G., & Cusi, K. J. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101092 · Cited by 41 · see citing works
Confounding factors of non-invasive tests for nonalcoholic fatty liver disease
Wai, J. W., Fu, C., & Wong, V. W. (2020) · Journal of Gastroenterology · doi:10.1007/s00535-020-01686-8 · Cited by 41 · see citing works
Endpoints in NASH Clinical Trials: Are We Blind in One Eye?
Lonardo, A., Ballestri, S., Mantovani, A., Targher, G., & Bril, F. (2024) · Metabolites · doi:10.3390/metabo14010040 · Cited by 34 · see citing works
Effect of Mastiha supplementation on NAFLD: The MAST4HEALTH Randomised, Controlled Trial
Amerikanou, C., Kanoni, S., Kaliora, A. C., Barone, A., Bjelan, M., D’Auria, G., Gioxari, A., Gosalbes, M. J., Mouchti, S., Stathopoulou, M. G., et al. (2021) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202001178 · Cited by 33 · see citing works
Romualdo, G. R., da Silva, T. C., Landi, M. F. D. A., Morais, J. Á., Barbisan, L. F., Vinken, M., de Oliveira, C. P. M. S., & Cogliati, B. (2020) · Environmental Toxicology · doi:10.1002/tox.23021 · Cited by 31 · see citing works
Hsueh, R.-C., Wu, W.-J., Lin, C.-L., Liu, C.-J., Huang, Y.-W., Hu, J.-T., Wu, C.-F., Sung, F.-Y., Liu, W.-J., & Yu, M.-W. (2022) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s355540 · Cited by 29 · see citing works
Pathologic Diagnosis of Nonalcoholic Fatty Liver Disease
Lai, J., Wang, H. L., Zhang, X., Wang, H., & Liu, X. (2021) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2021-0339-ra · Cited by 27 · see citing works
Yu, S., Jiang, J., Li, Q., Liu, X., Wang, Z., Yang, L., & Ding, L. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.855008 · Cited by 23 · see citing works
Chen, J. Y. S., Chua, D., Lim, C. O., Ho, W. X., & Tan, N. S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010158 · Cited by 23 · see citing works
Bril, F., Pearce, R. W., Collier, T. S., & McPhaul, M. J. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac565 · Cited by 21 · see citing works
Hameed, I., Hayat, J., Marsia, S., Samad, S. A., Khan, R., Siddiqui, O. M., Khan, M. O., Malik, S., Fatima, K., Fudim, M., et al. (2023) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2023.102111 · Cited by 19 · see citing works
Liu, Y., Zhang, M., Huang, Y., Zhang, Y., Chen, Z., Guan, J., Xia, S., & Liao, J. (2025) · Journal of Molecular Medicine · doi:10.1007/s00109-025-02599-w · Cited by 21 · see citing works
Noureddin, N., Schattenberg, J. M., Alkhouri, N., & Noureddin, M. (2020) · Hepatology Communications · doi:10.1002/hep4.1473 · Cited by 18 · see citing works
Exosomal microRNAs and Progression of Nonalcoholic Steatohepatitis (NASH)
Qi, X., & Lai, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113501 · Cited by 14 · see citing works
Syed‐Abdul, M. M., Moore, M. P., Wheeler, A. A., Ganga, R., Diaz‐Arias, A. A., Petroski, G. F., Rector, R. S., Ibdah, J. A., & Parks, E. J. (2023) · Journal of Nutrition · doi:10.1016/j.tjnut.2023.09.018 · Cited by 14 · see citing works
Hamilton, G., Schlein, A. N., Wolfson, T. J., Cunha, G. M., Fowler, K. J., Middleton, M. S., Loomba, R. S., & Sirlin, C. B. (2020) · NMR in Biomedicine · doi:10.1002/nbm.4286 · Cited by 14 · see citing works
Common Transcriptional Program of Liver Fibrosis in Mouse Genetic Models and Humans
Cokan, K. B., Urlep, Ž., Moškon, M., Mraz, M., Kong, X. Y., Eskild, W., Rozman, D., Juvan, P., & Režen, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020832 · Cited by 13 · see citing works
Predicting NASH response with liver fat: Are we back to square one?
Wong, V. W. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.10.024 · Cited by 13 · see citing works
Nanoformulations for the diagnosis and treatment of metabolic dysfunction-associated steatohepatitis
Qin, X., & Liu, J. (2024) · Acta Biomaterialia · doi:10.1016/j.actbio.2024.06.014 · Cited by 12 · see citing works
Nonalcoholic Fatty Liver Disease (NAFLD) for Primary Care Providers: Beyond the Liver
Leiva, E. G., & Bril, F. (2020) · Current Hypertension Reviews · doi:10.2174/1573402116999201209203534 · Cited by 11 · see citing works
Recent advances in NAFLD: current areas of contention
Jennison, E., & Byrne, C. D. (2023) · Faculty Reviews · doi:10.12703/r/12-10 · Cited by 10 · see citing works
Zhi, Y., Dong, Y., Li, X., Zhong, W., Lei, X., Tang, J. T., & Mao, Y. (2024) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3846 · Cited by 9 · see citing works
Albert, S. G., & Wood, E. M. (2021) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2021.102232 · Cited by 8 · see citing works
Zhyzhneuskaya, S. V., Al‐Mrabeh, A. H., Peters, C., Barnes, A. C., Hollingsworth, K. G., Welsh, P., Sattar, N., Lean, M. E. J., & Taylor, R. (2025) · Diabetic Medicine · doi:10.1111/dme.15462 · Cited by 6 · see citing works
Karagiannakis, D. S., Stefanaki, K., Paschou, S. Α., Papatheodoridi, Μ., Tsiodras, S., & Παπάνας, Ν. (2024) · HORMONES · doi:10.1007/s42000-024-00625-z · Cited by 4 · see citing works
Impact of the Analytical Approach on the Reliability of MRI-Based Assessment of Hepatic Fat Content
Burhans, M. S., Balu, N., Schmidt, K. A., Cromer, G., Utzschneider, K. M., Schur, E. A., Holte, S., Randolph, T. W., & Kratz, M. (2020) · Current Developments in Nutrition · doi:10.1093/cdn/nzaa171 · Cited by 4 · see citing works
A májbetegségek súlyosságának és prognózisának nem invazív vizsgálómódszerei
Pár, G. (2023) · Orvosi Hetilap · doi:10.1556/650.2023.32780 · Cited by 4 · see citing works
Improving NASH with a little help from thyromimetics
Ratziu, V. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32731-x · Cited by 3 · see citing works
Common transcriptional programme of liver fibrosis in mouse genetic models and humansPreprint
Cokan, K. B., Urlep, Ž., Moškon, M., Mraz, M., Kong, X. Y., Eskild, W., Rozman, D., Juvan, P., & Režen, T. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.11.02.364901
da Silva, D. G., Rodrigues, B. F. B., Brito, J. D. S., & Amato, A. A. (2023) · Journal of Digestive Diseases and Hepatology · doi:10.29011/2574-3511.100090
Kim, S. H. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70516
Molecular smugglers in obesity-driven MASLD: Snitching on adipose-derived extracellular vesicles
Chen, Q., Shevchenko, T., Zhan, D., Ma, N., Lefere, S., Boeckmans, J., Kock, J. D., Goethem, F. V., He, Y., Vanhaecke, T., et al. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.08.025
Teng, L., Luo, L., Shao, C., Sun, Y., Lai, J., 曹筱佩, Dong, Z., Ye, J., & Zhong, B. (2026) · Journal of the American Nutrition Association · doi:10.1080/27697061.2026.2742270
- Authors
- Bril, F., Barb, D., Lomonaco, R., Lai, J., & Cusi, K.
- Affiliations
- University of Florida Health (US)
- University of Florida (US)
- Corresponding author
- Cusi, Kenneth
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2020-03
- Volume
- 72
- Issue
- 3
- Pages
- 401-410
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2978847536
- Cited by
- 55
- References
- 47
- Citations by year
- 2026: 3 · 2025: 1 · 2024: 8 · 2023: 8 · 2022: 11 · 2021: 9 · 2020: 13 · 2019: 2
- FWCI
- 6.66
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Advanced MRI Techniques and Applications
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- nonalcoholic steatohepatitis, liver fat quantification, magnetic resonance spectroscopy, pioglitazone, liver histopathology, NAFLD activity score, liver fibrosis, lobular inflammation, hepatocyte ballooning, treatment response biomarkers
- MeSH terms
- Pioglitazone, Adult, Biopsy, Female, Humans, Hypoglycemic Agents, Inflammation, Liver, Liver Cirrhosis, Longitudinal Studies, Magnetic Resonance Imaging, Male, Middle Aged, Texas, Triglycerides, Biomarkers, Treatment Outcome, Non-alcoholic Fatty Liver Disease, Proton Magnetic Resonance Spectroscopy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
